Carisma Therapeutics Balance Sheet Health
Financial Health criteria checks 1/6
Carisma Therapeutics has a total shareholder equity of $-11.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $42.1M and $53.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$28.13m |
| Equity | -US$11.13m |
| Total liabilities | US$53.18m |
| Total assets | US$42.06m |
Recent financial health updates
Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky
Sep 02
We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate
Mar 26Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation
Oct 05We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely
Jun 15Recent updates
Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 28%
Dec 06Companies Like Carisma Therapeutics (NASDAQ:CARM) Could Be Quite Risky
Sep 02US$8.40: That's What Analysts Think Carisma Therapeutics, Inc. (NASDAQ:CARM) Is Worth After Its Latest Results
May 12Investors Don't See Light At End Of Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Tunnel And Push Stock Down 26%
Apr 19We're A Little Worried About Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Rate
Mar 26Lacklustre Performance Is Driving Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 26% Price Drop
Jan 21The Market Doesn't Like What It Sees From Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Revenues Yet As Shares Tumble 27%
Dec 07Analyst Forecasts Just Became More Bearish On Carisma Therapeutics, Inc. (NASDAQ:CARM)
Nov 12Here's Why We're Watching Carisma Therapeutics' (NASDAQ:CARM) Cash Burn Situation
Oct 05We're Hopeful That Carisma Therapeutics (NASDAQ:CARM) Will Use Its Cash Wisely
Jun 15Financial Position Analysis
Short Term Liabilities: CARM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CARM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CARM is debt free.
Reducing Debt: CARM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CARM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CARM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 48.3% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 01:55 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Carisma Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Justin Zelin | BTIG |
| Naureen Quibria | Capital One Securities, Inc. |